127 related articles for article (PubMed ID: 32037360)
1. [Preoperative C-reactive protein predicts recurrence after curative resection in advanced gastric cancer patients receiving postoperative adjuvant chemotherapy using S-1].
Shimizu T; Ishizuka M; Sakuraoka Y; Shiraki T; Abe A; Mori S; Iso Y; Takagi K; Aoki T; Kubota K
Nihon Shokakibyo Gakkai Zasshi; 2020; 117(2):150-156. PubMed ID: 32037360
[TBL] [Abstract][Full Text] [Related]
2. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
3. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
Zhang Q; Qian Y; Yin Y
Eur J Clin Pharmacol; 2021 Dec; 77(12):1791-1804. PubMed ID: 34275019
[TBL] [Abstract][Full Text] [Related]
4. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H
Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
[TBL] [Abstract][Full Text] [Related]
7. Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
Watanabe H; Hayashi T; Komori K; Hara K; Maezawa Y; Kano K; Shimoda Y; Fujikawa H; Aoyama T; Yamada T; Yamamoto N; Cho H; Ito H; Shiozawa M; Yukawa N; Morinaga S; Yoshikawa T; Rino Y; Masuda M; Ogata T; Oshima T
Anticancer Res; 2020 Mar; 40(3):1683-1690. PubMed ID: 32132075
[TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
[TBL] [Abstract][Full Text] [Related]
10. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer.
Ogawa K; Honda M; Akashi Y; Inagawa S; Kaneda A; Hori S; Owada Y; Ohara Y; Hisakura K; Enomoto T; Shimomura O; Takahashi K; Oda T
Int J Clin Oncol; 2020 Oct; 25(10):1807-1813. PubMed ID: 32533352
[TBL] [Abstract][Full Text] [Related]
12. [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
Sakurai Y; Kamoshida S; Furuta S; Sunagawa R; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1147-55. PubMed ID: 18633253
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
14. High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients.
Nakazawa N; Sohda M; Ide M; Shimoda Y; Ubukata Y; Kuriyama K; Hara K; Sano A; Sakai M; Yokobori T; Ogawa H; Oyama T; Shirabe K; Saeki H
Oncology; 2021; 99(11):732-739. PubMed ID: 34392246
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
[TBL] [Abstract][Full Text] [Related]
16. Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.
Okubo K; Arigami T; Matsushita D; Tanaka T; Tsuruda Y; Noda M; Sasaki K; Mori S; Kurahara H; Ohtsuka T
Oncology; 2021; 99(6):380-388. PubMed ID: 33677434
[TBL] [Abstract][Full Text] [Related]
17. Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
Yen CC; Shan YS; Chao YJ; Liao TK; Chen IS; Huang HY; Liu IT; Yen CJ
BMC Cancer; 2021 Jul; 21(1):796. PubMed ID: 34243732
[TBL] [Abstract][Full Text] [Related]
18. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
[TBL] [Abstract][Full Text] [Related]
19. Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
Tanaka H; Tamura T; Toyokawa T; Muguruma K; Miki Y; Kubo N; Sakurai K; Hirakawa K; Ohira M
Anticancer Res; 2018 Jun; 38(6):3745-3751. PubMed ID: 29848737
[TBL] [Abstract][Full Text] [Related]
20. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
Aoyama T; Sato T; Maezawa Y; Kano K; Hayashi T; Yamada T; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
Int J Clin Oncol; 2017 Jun; 22(3):476-483. PubMed ID: 28176023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
